Topic

All

25
Jun
2020

The Exponential Curves Re-Emerge

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.   Subscribe Now   Sign in to your account.
11
Jun
2020

AstraZeneca Opens Its Digital Komono

AstraZeneca has emerged with a reputation as one of the industry’s most imaginative pharmas – it was named the “most innovative” global pharma company by IDEA Pharma in November 2019, and was cast as Gallant to GSK’s Goofus in a recent Financial Times piece examining their contrasting trajectories. In this context, I was especially excited when I saw what looked...
Read More
11
Jun
2020

Inconvenient Truths and Rays of Light

The information world that we built sometimes has a way of distracting us. It downplays and marginalizes what’s important. Not this week. Let’s start with a few timely, inconvenient truths. As of this writing on June 11: The US has 113,865 dead from COVID-19 and counting. 2 million+ confirmed cases. 20,000 new cases adding up every day. 21 states are...
Read More
10
Jun
2020

Fighting COVID-19 & Racism: Andy Plump on The Long Run

Today’s guest on The Long Run is Andrew Plump. Andy is the president of research and development, and a member of the board of directors, at Takeda Pharmaceutical. Takeda doesn’t get a lot of attention in the US, but it’s one of the world’s biggest pharmaceutical companies by revenue, ranking a little behind AbbVie and a little ahead of Bristol-Myers...
Read More
10
Jun
2020

Making Drugs at the Edge of Reason

Editor’s Note: This essay is excerpted from “Biotechnology in the Time of COVID-19” edited by Dr. Jeremy M. Levin. It is printed with permission from RosettaBooks. The book is available exclusively on Amazon. A few days ago, I Zoomed with a Hollywood Squares display of faces on my laptop: the top 60 leaders of VIR Biotechnology, a young company founded...
Read More
10
Jun
2020

Let’s Turn the Black Nod Into a Collective Nod

I first met Ken Frazier, the CEO of Merck, at the JP Morgan Healthcare Conference in San Francisco in January 2018. It was my second year as an operator in biotech. I was still getting familiar with the whole bewildering experience of JPM. I was trained as a cancer immunologist at Dartmouth, did a stint in life sci strategy consulting,...
Read More
1 2 3 39